We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-1.89%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.15B
AUM Growth
-$253M
Cap. Flow
-$97.3M
Cap. Flow %
-8.43%
Top 10 Hldgs %
65.98%
Holding
89
New
12
Increased
29
Reduced
25
Closed
19

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$63.1M
2
NTRA icon
Natera
NTRA
+$45.2M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.6M
4
ILMN icon
Illumina
ILMN
+$14.6M
5
MCRB icon
Seres Therapeutics
MCRB
+$9.91M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$67.4M
2
AVTR icon
Avantor
AVTR
+$28M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$21.6M
4
ARGX icon
argenx
ARGX
+$16.9M
5
FATE icon
Fate Therapeutics
FATE
+$16.9M

Sector Composition

Rank Sector Weight
1 Healthcare 72.39%
2 Miscellaneous 27.61%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISRG icon
51
Intuitive Surgical
ISRG
$132B
$1.71M 0.15%
9,125
+534
+6% +$115K
XOMA
52
DELISTED
Xoma
XOMA
$1.58M 0.14%
+88,402
New +$1.82M
IQV icon
53
IQVIA
IQV
$43.1B
$1.5M 0.13%
8,297
+2,273
+38% +$498K
LH icon
54
Labcorp
LH
$27.2B
$1.48M 0.13%
8,419
+2,187
+35% +$448K
AVTR icon
55
Avantor
AVTR
$9.86B
$1.46M 0.13%
74,452
-1,045,723
-93% -$28M
WHWK
56
Whitehawk Therapeutics
WHWK
$263M
$1.44M 0.12%
101,918
+1,101
+1% +$14.5K
RVTY icon
57
Revvity
RVTY
$14.4B
$1.32M 0.11%
10,930
+637
+6% +$89.8K
ARGX icon
58
argenx
ARGX
$64B
$1.24M 0.11%
3,502
-45,634
-93% -$16.9M
MIST icon
59
Milestone Pharmaceuticals
MIST
$144M
$1.17M 0.1%
126,826
-20,339
-14% -$154K
RGEN icon
60
Repligen
RGEN
$9.95B
$681K 0.06%
3,641
-2,052
-36% -$433K
CYH icon
61
CALL
Community Health Systems
CYH
$413M
$673K 0.06%
312,900
+112,900
+56% +$374K
MRVI icon
62
CALL
Maravai LifeSciences
MRVI
$1.14B
$613K 0.05%
+24,000
New +$602K
HSKA
63
DELISTED
Heska Corp
HSKA
$506K 0.04%
6,943
-829
-11% -$73.3K
ACIU icon
64
AC Immune
ACIU
$263M
$394K 0.03%
124,589
– –
CABA icon
65
Cabaletta Bio
CABA
$529M
$364K 0.03%
+560,466
New +$675K
SNDA icon
66
Sonida Senior Living
SNDA
$1.8B
$191K 0.02%
11,791
-3,418
-22% -$66.8K
THRD
67
DELISTED
Third Harmonic Bio
THRD
$190K 0.02%
+10,000
New +$180K
ELDN icon
68
Eledon Pharmaceuticals
ELDN
$260M
$187K 0.02%
67,743
+8,678
+15% +$27.6K
CBIO
69
Crescent Biopharma
CBIO
$659M
$55.5K ﹤0.01%
1,006
– –
BOLT icon
70
Bolt Biotherapeutics
BOLT
$7.35M
$46.1K ﹤0.01%
1,559
– –
ALNY icon
71
Alnylam Pharmaceuticals
ALNY
$31.7B
– –
-78,987
Closed -$11.5M
ANAB icon
72
AnaptysBio
ANAB
$1.67B
– –
-182,717
Closed -$3.71M
ARKK icon
73
PUT
ARK Innovation ETF
ARKK
$6.46B
– –
-90,000
Closed -$3.59M
AZN icon
74
CALL
AstraZeneca
AZN
$252B
– –
-150,150
Closed -$19.8M
AZN icon
75
AstraZeneca
AZN
$252B
– –
-510,165
Closed -$67.4M
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Eversept Partners held 89 positions worth $1.15B, down 18% from $1.41B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Eversept Partners withdrew a net $97.3M in Q3 2022, closing 19 positions and reducing 25 holdings. Its most notable exit was AstraZeneca, an estimated $67.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 70% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Eversept Partners opened a new position in Seres Therapeutics worth $12.4M.

  • Eversept Partners's largest Q3 2022 buy was Seres Therapeutics: 96,791 shares worth $12.4M.
  • Eversept Partners added most to GSK in Q3 2022, an estimated $63.1M increase.
  • Eversept Partners's biggest Q3 2022 reduction was Avantor, cutting an estimated $28M.
  • Eversept Partners fully exited AstraZeneca in Q3 2022, selling an estimated $67.4M.
  • Eversept Partners's ten largest holdings make up 66% of its $1.15B portfolio in Q3 2022.
  • Eversept Partners opened 12 new positions and closed 19 in Q3 2022.
  • Eversept Partners's portfolio value fell 18% quarter-over-quarter to $1.15B.

Based on Eversept Partners's 13F filing for Q3 2022, filed 14 Nov 2022.